Ciprofloxacin-hydrochloride-monohydrate-Bay-09867-hydrochloride-monohydrate-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemECiprofloxacinhydrochloridemonohydrateCat.No.:HY-B0356BCASNo.:86393-32-0Synonyms:Bay-09867hydrochloridemonohydrate分⼦式:C₁₇H₂₁ClFN₃O₄分⼦量:385.82作⽤靶点:Topoisomerase;Apoptosis;Antibiotic;Bacterial;MitochondrialMetabolism;ReactiveOxygenSpecies作⽤通路:CellCycle/DNADamage;Apoptosis;Anti-infection;MetabolicEnzyme/Protease;Immunology/Inflammation;NF-κB储存⽅式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性数据体外实验DMSO:5mg/mL(12.96mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制备储备液1mM2.5919mL12.9594mL25.9188mL5mM0.5184mL2.5919mL5.1838mL10mM0.2592mL1.2959mL2.5919mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/4MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESolubility:≥0.5mg/mL(1.30mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥0.5mg/mL(1.30mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥0.5mg/mL(1.30mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Ciprofloxacin(Bay-09867)hydrochloridemonohydrate⼀种⼝服有效的拓扑异构酶IV抑制剂。Ciprofloxacinhydrochloridemonohydrate诱导线粒体DNA和核DNA损伤并导致线粒体功能障碍和活性氧产⽣。Ciprofloxacinhydrochloridemonohydrate具有抗增殖活性并诱导细胞凋亡(apoptosis)。Ciprofloxacinhydrochloridemonohydrate⼀种氟喹诺酮类抗⽣素，具有强⼤的抗活性。IC50&TargetQuinolone体外研究Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(5-50μg/mL;0-24h;tendoncells)inhibitscellproliferationandcausescellcyclearrestattheG2/Mphase[1].Ciprofloxacin(Bay-09867)hydrochloridemonohydrateshowspotentactivityagainstY.pestisandB.anthraciswithMIC90of0.03μg/mLand0.12μg/mL,respectively[2].CellViabilityAssay[1]CellLine:TendoncellsConcentration:5,10,20and50μg/mLIncubationTime:24hoursResult:Decreasedthecellularityoftendoncells.CellCycleAnalysis[1]CellLine:TendoncellsConcentration:50μg/mLIncubationTime:24hoursResult:ArrestedcellcycleattheG2/Mphaseandinhibitedcelldivisionintendoncells.WesternBlotAnalysis[1]CellLine:TendoncellsConcentration:50μg/mLIncubationTime:0,6,12,17and24hours2/4MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEResult:Down-regulatedtheexpressionofCDK-1andcyclinBproteinandmRNA.Up-regulatedtheexpressionofPLK-1protein.体内研究Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(30mg/kg;i.p.;for24hours;BALB/cmice)hasprotectionagainstY.pestisinmurinemodelofpneumonicplague[3].Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(100mg/kg;i.g.;daily,for4weeks;C57BL/6Jmice)acceleratesaorticrootenlargementandincreasestheincidenceofaorticdissectionandrupturebydecreasesLOXlevelandincreasesMMPlevelsandactivityintheaorticwall[4].Ciprofloxacin(Bay-09867)hydrochloridemonohydrate(100mg/kg;i.g.;daily,for4weeks;C57BL/6Jmice)inducesDNAdamageandreleaseofDNAtothecytosol,mitochondrialdysfunction,andactivationofcytosolicDNAsensorsignaling.Ciprofloxacinlactateincreasesapoptosisandnecroptosisintheaorticwall[4].AnimalModel:BALB/cmice[3]Dosage:30mg/kgAdministration:Intraperitonealinjection;for24hoursResult:Reducedthelungbacterialloadinmurinemodelofpneumonicplague.AnimalModel:C57BL/6Jmice[4]Dosage:100mg/kgAdministration:Oralgavage;daily,for4weeksResult:HadaorticdestructionthatwasaccompaniedbydecreasedLOXexpressionandincreasedMMPexpressionandactivity.AnimalModel:C57BL/6Jmice[4]Dosage:100mg/kgAdministration:Oralgavage;daily,for4weeksResult:CausedmitochondrialDNAandnuclearDNAdamage,leadingtomitochondrialdysfunctionandROSproduction.Increasedapoptosisandnecroptosisintheaorticwall.户使⽤本产品发表的科研⽂献•NatCommun.2022Mar2;13(1):1116.•AdvSci(Weinh).2020Jul21;7(17):2001374.•IntJAntimicrobAgents.2018Aug;52(2):269-271.3/4MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE•EBioMedicine.2022Apr;78:103943.•MicrobiolSpectr.2022Apr25:e0251821.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].TsaiWC,et,al.Ciprofloxacin-mediatedcellproliferationinhibitionandG2/Mcellcyclearrestinrattendoncells.ArthritisRheum.2008Jun;58(6):1657-63.[2].SteenbergenJ,et,al.InVitroandInVivoActivityofOmadacyclineagainstTwoBiothreatPathogens,BacillusanthracisandYersiniapestis.AntimicrobAgentsChemother.2017Apr24;61(5):e02434-16.[3].HamblinKA,et,al.InhaledLiposomalCiprofloxacinProtectsagainstaLethalInfectioninaMurineModelofPneumonicPlague.FrontMicrobiol.2017Feb6;8:91.[4].LeMaireSA,et,al.EffectofCiprofloxacinonSusceptibilitytoAorticDissectionand